GlassScriptPhysician profile
Michael K Johnson
NPI 1932729282
$1,075.34
in general payments reported to CMS, 2019-2025
16 companies · $904 in 2025
The $904 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.48 · 2024: $142 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $198.79 | 2024-2025 | Airsupra, Breztri |
| Amgen INC. | $118.19 | 2024-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $110.56 | 2024-2025 | Ozempic, Rybelsus |
| Ucb, INC. | $108.66 | 2024-2025 | Briviact |
| Verona Pharma, INC. | $106.93 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $97.88 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $90.48 | 2024-2025 | |
| Abbvie INC. | $67.14 | 2024-2025 | |
| Neurelis, INC. | $49.24 | 2025 | Valtoco |
| Bayer Healthcare Pharmaceuticals INC. | $34.32 | 2025 | |
| Lilly USA, LLC | $18.47 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.88 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $15.13 | 2022 | |
| Pfizer INC. | $14.93 | 2025 | |
| Heartflow, INC. | $14.39 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.